• Ceftolozane-Tazobactam in Nosocomial Pneumonia: Structural a

  2026-06-18

  The referenced study rigorously details the development and clinical evaluation of ceftolozane-tazobactam as a potent alternative for treating nosocomial pneumonia, particularly ventilator-associated cases caused by multidrug-resistant Pseudomonas aeruginosa. Its structural modifications and pharmacodynamic properties enable effective Gram-negative coverage, setting a new benchmark for antibiotic stewardship in hospital settings.

• Haloprogin: Reference-Backed Antifungal and Antibacterial Ac

  2026-06-18

  The reference study by Harrison et al. (1970) established Haloprogin as a highly effective topical agent with broad-spectrum antifungal and selective antibacterial activity, demonstrating efficacy against dermatophytes, yeasts, and Gram-positive bacteria. Its direct comparison with tolnaftate revealed unique advantages, especially in treating dermatophytosis and Candida infections, providing foundational data for contemporary infection research.

• Resiniferatoxin (RTX): Data-Driven Solutions for Reliable TR

  2026-06-17

  This article addresses key laboratory challenges in pain and cytotoxicity research, offering practical, evidence-based guidance for deploying Resiniferatoxin (RTX, SKU BA7012) as a highly selective TRPV1 agonist. Scenario-driven Q&A blocks deliver actionable insights for experimental design, data interpretation, and vendor selection, highlighting why RTX from APExBIO stands out for reproducibility and precision.

• JNJ-10198409: Platelet-Derived Growth Factor Receptor Inhibi

  2026-06-17

  JNJ-10198409 offers precise, nanomolar inhibition of PDGF-BB receptor signaling, enabling robust suppression of tumor growth and angiogenesis in translational research. Its high potency and well-characterized workflow support reproducible results for cancer, fibrosis, and vascular biology studies.

• Mavorixafor’s Role in WHIM Syndrome: Phase 3 Trial Insights

  2026-06-16

  A recent phase 3 trial establishes mavorixafor, an oral CXCR4 antagonist, as a promising targeted therapy for WHIM syndrome, a rare immunodeficiency driven by CXCR4 mutations. The study demonstrates significant improvements in neutrophil and lymphocyte counts and a reduction in infection rates, marking a major advance over previous supportive treatments.

• Morin: Applied Protocols and Innovations in Disease Modeling

  2026-06-16

  Morin, a bioactive 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, enables advanced disease modeling and energy metabolism research with superior specificity and analytical versatility. Explore actionable workflows and troubleshooting strategies that unlock Morin's full potential as a dual-function modulator and fluorescent probe.

• Bioluminescent Probes for Immunoproteasome: Synthesis & Insi

  2026-06-15

  Loy and Trader introduce a synthetic protocol for a bioluminescent probe selective for the immunoproteasome (iCP), enabling direct monitoring of iCP activity in cellular and tissue assays. This innovation provides a valuable tool for studying iCP involvement in disease and for screening small-molecule modulators, addressing longstanding limitations of previous probes.

• Canagliflozin (SKU A8333): Reliable SGLT2 Inhibitor for Rena

  2026-06-15

  This article addresses real-world experimental challenges in cell viability and mitochondrial assays, demonstrating how Canagliflozin (SKU A8333) provides reproducible, data-driven solutions for glucose metabolism and kidney disease modeling. Leveraging authoritative literature and workflow optimization, it guides researchers on selecting and applying this potent SGLT2 inhibitor in metabolic and renal studies.

• Scalable Bioreactor Platform for Therapeutic MSC-EV Producti

  2026-06-14

  Gong et al. introduce a robust, scalable platform for producing mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) using extended pluripotent stem cells (EPSCs) and bioreactor technology. This standardized approach overcomes key barriers of donor variability and manufacturing scale, enabling consistent EVs with therapeutic potential for regenerative medicine.

• Targeting CYP2B6 in Glioblastoma via ATF5 Peptide Downregula

  2026-06-13

  This study demonstrates that a cell-penetrating dominant-negative ATF5 peptide effectively downregulates CYP2B6 in glioblastoma cells, uncovering a regulatory axis with implications for precision oncology drug dosing. The findings highlight a novel strategy to modulate drug metabolism in tumor cells, potentially improving therapeutic efficacy and safety.

• Anlotinib Hydrochloride in IADSRCT: Case Evidence and Resear

  2026-06-12

  The referenced case report documents the first successful use of anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, in treating metastatic intra-abdominal desmoplastic small round cell tumor (IADSRCT). This work highlights both the clinical potential and the mechanistic rationale for targeting angiogenic and proliferative pathways in rare, aggressive sarcomas.

• PK/PD Analysis of Gamithromycin in Murine Pasteurella Infect

  2026-06-12

  This study rigorously defines pharmacokinetic and pharmacodynamic (PK/PD) indices for Gamithromycin in a neutropenic murine lung infection model of Pasteurella multocida. By linking unbound drug exposure to antibacterial efficacy, the research provides actionable parameters for optimized dosing in veterinary respiratory disease research.

• Tigecycline in Antimicrobial Research: Protocols and Optimiz

  2026-06-11

  Tigecycline's unique glycylcycline scaffold empowers labs to dissect multidrug-resistant mechanisms and optimize infection models with precision. This guide translates new resistance gene insights into practical protocols and troubleshooting strategies—making APExBIO’s Tigecycline an essential tool for advanced antimicrobial studies.

• Ionizing Radiation Alters Neural Differentiation via PI3K-ST

  2026-06-11

  This study demonstrates that ionizing radiation (IR) induces aberrant neuronal differentiation in C17.2 mouse neural stem-like cells through coordinated PI3K-STAT3-mGluR1 and PI3K-p53 signaling. The findings highlight the complex molecular pathways underlying radiation-induced changes in neurogenesis, with implications for understanding brain dysfunction following radiotherapy.

• Actinomycin D: Applied Workflows for Transcriptional Stress

  2026-06-10

  Actinomycin D (ActD) is the gold-standard transcriptional inhibitor empowering researchers to dissect cellular stress, apoptosis, and mRNA dynamics in complex cancer models. This article delivers hands-on workflow enhancements, troubleshooting advice, and strategic insights for leveraging APExBIO’s trusted Actinomycin D in cutting-edge experimental contexts.

16747 records 1/1117 page Next 12345 下5页 Last page